Xueke Liu
Jinhua, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Pseudogene revival drives repeated adaptation in fission yeast.
Journal: Molecular biology and evolution
Published: January 14, 2026
RNA methylation: A potential therapeutic target in autoimmune disease.
Journal: International reviews of immunology
Published: November 17, 2023
ETS-1/c-Met drives resistance to sorafenib in hepatocellular carcinoma.
Journal: American journal of translational research
Published: August 28, 2022
Targeted Delivery of Glypican 3 (GPC3) Antibody-Modified MicroRNA (miR let-7b-5p) Polymer Nanoparticles to Sorafenib-Resistant Hepatsocellular Carcinoma Cells.
Journal: Journal of biomedical nanotechnology
Published: January 21, 2022
Retraction Note: The PI3K/mTOR Dual Inhibitor BEZ235 Nanoparticles Improve Radiosensitization of Hepatoma Cells Through Apoptosis and Regulation DNA Repair Pathway.
Journal: Nanoscale research letters
Published: December 16, 2021
Development of a Sandwich Chemiluminescence Immunoassay for the Detection of Intact Procollagen Type I N Propeptide with Magnetic Nanosphere Carrier Technology.
Journal: Journal of biomedical nanotechnology
Published: September 21, 2021
Development of chemiluminescence method based on serum type I collagen hydroxyl terminal peptide β special sequence (β-CTX).
Journal: Scandinavian journal of clinical and laboratory investigation
Published: July 30, 2021
Viral Haplotypes in COVID-19 Patients Associated With Prolonged Viral Shedding.
Journal: Frontiers in cellular and infection microbiology
Published: May 26, 2021
BEZ235 Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib by Inhibiting PI3K/AKT/mTOR and Inducing Autophagy.
Journal: BioMed research international
Published: January 31, 2021
LY3214996 relieves acquired resistance to sorafenib in hepatocellular carcinoma cells.
Journal: International journal of medical sciences
Published: July 29, 2020
Increased efficacy of gefitinib on cisplatin-resistant wild-type epidermal growth factor receptor non-small cell lung cancer cells.
Journal: Translational cancer research
Published: March 10, 2020
Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells.
Journal: Journal of cancer research and clinical oncology
Published: February 23, 2020
Last Updated: 09/26/2026